Abstract

Exosomes have emerged as important mediators of diverse biological functions including tumor suppression, tumor progression, invasion, immune escape and cell-to-cell communication, through the release of molecules such as mRNAs, miRNAs, and proteins. Here, we identified differentially expressed exosomal miRNAs between normal epithelial ovarian cell line and both resistant and sensitive ovarian cancer (OC) cell lines. We found miR-940 as abundant in exosomes from SKOV3-IP1, HeyA8, and HeyA8-MDR cells. The high expression of miR-940 is associated with better survival in patients with ovarian serous cystadenocarcinoma. Ectopic expression of miR-940 inhibited proliferation, colony formation, invasion, and migration and triggered G0/G1 cell cycle arrest and apoptosis in OC cells. Overexpression of miR-940 also inhibited tumor cell growth in vivo. We showed that proto-oncogene tyrosine-protein kinase (SRC) is directly targeted by miR-940 and that miR-940 inhibited SRC expression at mRNA and protein levels. Following this inhibition, the expression of proteins downstream of SRC, such as FAK, paxillin and Akt was also reduced. Collectively, our results suggest that OC cells secrete the tumor-suppressive miR-940 into the extracellular environment via exosomes, to maintain their invasiveness and tumorigenic phenotype.

Highlights

  • Ovarian cancer (OC) is one of the leading causes of death among women with gynecologic malignancies

  • We found that combination treatment resulted in synergistic effect on invasiveness of ovarian cancer cells (Supplementary Figure 6). miR-940 treatment in combination with showed that proto-oncogene tyrosineprotein kinase (SRC) small interfering RNA (siRNA) led to significantly lower number of invaded cells compared to SRC siRNA alone (p

  • We found that miR-940 is highly expressed in exosomes derived from cancer cells, while not in exosomes from normal cells

Read more

Summary

Introduction

Ovarian cancer (OC) is one of the leading causes of death among women with gynecologic malignancies. According to the National Cancer Institute, approximately 21,290 new cases and 14,180 deaths were reported in 2015 [1]. The majority of cases are diagnosed at an advanced stage, and an overall 5-year survival rate of approximately 40%. Most patients with OC relapse, highlighting the urgent need for new treatment strategies for the elimination of OC. Strategies targeting only tumor cells have proven to be unsuccessful to eliminate OC and prevent metastasis. Www.impactjournals.com/oncotarget understanding tumor and tumor microenvironment and identification of novel “molecular targets/ pathways” required for the development of the highly effective therapies to eradicate OC and improve patient survival

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.